Featured Research Search Results

Treating Advanced Endometrial or Ovarian Cancer with Targeted Therapies (ComboMATCH)

Clinicaltrials.gov identifier:
NCT05554328

Treatment
Phase 2 treatment study for recurrent endometrial or ovarian cancer

Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies

Clinicaltrials.gov identifier:
NCT06974110

Treatment
Treatment study for people with advanced or metastatic cancers

Comparing an Investigational Targeted Drug AZD5335 to Standard Treatments in People With Platinum‑Resistant Ovarian Cancer (TREVI‑OC‑01)

Clinicaltrials.gov identifier:
NCT07218809

Treatment
Phase 3 treatment study for platinum-resistant ovarian cancer

Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)

Clinicaltrials.gov identifier:
NCT05059444

Treatment
Post-treatment study to monitor for recurrence

Treating Advanced Breast or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)

Clinicaltrials.gov identifier:
NCT05372640

Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors

Treating Advanced Cancers with DNA-Repair Mutations Using MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib

Clinicaltrials.gov identifier:
NCT06545942

Treatment
Treatment study for people with advanced or metastatic cancers

Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT05932862

Treatment
Treatment study for people with advanced solid tumors

Using a PARP Inhibitor and Oral Chemotherapy to Treat Advanced Solid Tumors with a Mutation in BRCA1, BRCA2, PALB2, ATM or CHEK2

Clinicaltrials.gov identifier:
NCT06177171

Treatment
Phase 1 treatment study for metastatic solid tumors

Maintenance Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer with a BRCA Mutation or a Biomarker Called HRD

Clinicaltrials.gov identifier:
NCT06580314

Treatment
Phase 3 ovarian cancer treatment study for people with BRCA mutation or HRD

A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with Inherited or Tumor Mutations

Clinicaltrials.gov identifier:
NCT04890613

Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer

Treating Advanced or Metastatic Cancers with a New PARP Inhibitor (GS-0201) Alone or Combined with Other Drugs

Clinicaltrials.gov identifier:
NCT06167317

Treatment
Treatment study for people with advanced or metastatic solid tumors

A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)

Clinicaltrials.gov identifier:
NCT04251052

Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries

Sexual Health and Rehabilitation Online (SHAREonline): An Educational Intervention for Young Women after Cancer

Clinicaltrials.gov identifier:
NCT06458049

Quality of Life
An online study comparing two educational interventions for female cancer survivors experiencing sexual health changes

Study of the Drug Olvi-Vec in Women with Ovarian Cancer

Clinicaltrials.gov identifier:
NCT05281471

Treatment
Treatment for women diagnosed with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer or whose cancer did not respond to prior chemotherapy

Understanding the Emotional and Social Experiences of Individuals Diagnosed with Ovarian Cancer

Surveys, Registries, Interviews
Survey for people diagnosed with ovarian cancer

New Treatment in People with Triple Negative Breast Cancer or Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT06022029

Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas

Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families

Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy

Clinicaltrials.gov identifier:
NCT05287451

Prevention
Prevention study for women at high risk for ovarian cancer